Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
– Four posters highlight TERLIVAZ research on the potential impact of dosing and outcomes in key subpopulations of adults with HRS with rapid reduction in kidney function1 –